Authors
Ahmadjon Ahmadjonov, Durr-E-Shahwar Malik, Otabek Kuziev, Shakhnoza Toshova, Aseel Smerat, Mohammad Adi, Ahmed Ashraf
Published in
Clinical medicine insights. Endocrinology and diabetes. Volume 19. Pages 11795514261490259. Epub Sep 11, 2026.
Abstract
Ketosis-prone diabetes (KPD) is a heterogeneous diabetes phenotype in which some patients with preserved β-cell function can achieve insulin independence after diabetic ketoacidosis (DKA). The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in maintaining remission in A-β+ KPD remains uncertain because of concerns regarding ketoacidosis risk. We report the case of a 45-year-old man who presented with severe DKA and was classified as A-β+ KPD based on negative islet autoantibodies and preserved C-peptide secretion. Following acute management, structured insulin withdrawal was performed, and dapagliflozin was initiated at week 4 with intensive metabolic monitoring. Over 12 months, the patient achieved sustained insulin-free remission, with significant improvements in HbA1c (12.1% to 6.4%), robust recovery of stimulated C-peptide (peak 4.8 ng/mL), and a continuous glucose monitoring (CGM) time-in-range of 82%, without recurrence of ketosis. This case suggests that in carefully selected A-β+ KPD patients with preserved β-cell reserve, SGLT2 inhibition may be safely integrated into the remission phase under close surveillance. However, these findings are hypothesis-generating, and the contribution of dapagliflozin to remission cannot be determined from a single uncontrolled observation. Prospective studies are required before this strategy can be recommended for routine use.
PMID:
42732149
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0